LeonaBio, Inc. LONA
LeonaBio, Inc. (Nasdaq: LONA) is an oncology drug developer. Its lead program, Lasofoxifene, is in Phase 3 for ER+/HER2- metastatic breast cancer with ESR1 mutations. Its next catalyst on record is Lasofoxifene: Topline results of the ELAINE-3 trial (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Lasofoxifene — Topline results of the ELAINE-3 trial (date not stated). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Lasofoxifene (ELAINE-3) | Metastatic breast cancer with ESR1 mutations | small molecule | Phase 3 |
| Brelgometon | ALS (Phase 2 in planning; first-in-human Phase 1 completed) | small molecule | Phase 1 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.